Update on the Embedded Value of the Life insura...
Regulated information* - 1 April 2011 (08.00 a.m. CEST)
Highlights
* The embedded value of KBC's life insurance business came to 3.7 billion
euros (11.0 euros per share) on 31 December 2010
* The value of new business for 2010 totalled 75 million euros (0.22 euros per
share), and the new business margin amounted to 30.1% (measured on an
Annualised Premium Equivalent (APE) basis) and 3.1% (measured on a Present
Value of New Business Premiums (PVNBP) basis)
* The scope of the model didn't change in 2010 (versus 2009)
* Market Consistent valuation methodology used
* Explanatory presentation available on www.kbc.com
Market Consistent Embedded Value, update as at 31 December 2010
The Market Consistent Embedded Value (MCEV) reflects the economic value of the
life insurance portfolio by projecting anticipated future cashflows and using
market consistent assumptions, among other factors.
At year-end 2010, the MCEV of the group's life insurance activities stood at
3 724 million euros (11.0 euros per share).
To calculate the MCEV, the Value of Business In Force (VBI) is added to the
Adjusted Net Asset Value (ANAV). The ANAV of the life insurance business,
amounted to 3 043 million euros, while the VBI came to 681 million euros.
The total MCEV increased 11% year-on-year. The ANAV went up by as much as 19%
year-on-year, thanks mainly to the profit generated in 2010 and the dividends
received from entities not in the scope for MCEV calculation. The Value of
Business In Force (VBI) decreased 15% year-on-year, the result largely of the
decrease in swap reference rates which impact the 'guaranteed-interest products'
portfolio. The liquidity premium above the swap rates applied for KBC Insurance
decreased from 20 basis points in 2009 to 14 basis points. No liquidity premium
was applied for the CEER Business Unit.
The value added by new policies written in 2010 (Value of New Business) amounted
to 75 million euros. The 42% year-on-year increase can be explained mainly by
the more profitable business such as unit-linked and term insurance. The new
business margin on an Annualised Premium Equivalent basis came to 30.1%, or
3.1% when compared with the present value of new business premiums.
The economic sensitivities on MCEV remained limited. If equity markets had been
10% lower at the start of the cashflow projection, the resulting MCEV would not
have been materially lower. Also, if the interest yield curve had shifted up by
100 basis points at the start of the cashflow projection, the resulting MCEV
would not have been materially impacted.
Methodology and scope
KBC applies a Market Consistent Embedded Value (MCEV) framework.
The scope of KBC's MCEV model is the life insurance business in Belgium, the
Czech Republic and Poland. This scope corresponds to 98% of the life insurance
reserves and 97% of the life insurance premium inflow in 2010. The book value of
the corresponding shareholders' equity amounts to 3.2 billion euros. As was the
case the previous year, the business of Fidea and Vitis was not taken into
account.
The model's scope covers the entire in-house value chain from origination to
distribution of life insurance policies. Some 6% of the MCEV and around 22% of
the Value of New Business was generated by the Asset Management division through
managing investment units linked to insurance policies.
To calculate the MCEV, the Value of Business In Force (VBI) is added to the
Adjusted Net Asset Value (ANAV, adjusted shareholders equity allocated to the
life insurance business). The VBI equals the sum of the discounted values of all
future profits of the life portfolio. It explicitly takes the cost of written
guarantees and embedded options into account, as well as the frictional costs
and a capital charge for non-hedgeable risks (such as longevity, operational
risks, etc.).
The Value of New Business (VNB) includes the value at point of sale of new
policies written in 2010 and is calculated in the same way as the VBI.
The published figures do not include:
·        the value of the non-life insurance business;
·        the value of the life insurance business in Slovakia, Bulgaria,
Hungary and Slovenia;
·        the value of the expected future life insurance business.
Valuing both the non-life and life insurance businesses in Slovakia, Bulgaria,
Hungary and Slovenia (out of scope for the MCEV calculation) at 1.0 times book
value, implies another 2.1 euros per share (besides the 11.0 euros MCEV per
share for the life business).
Towers Watson, the actuarial consultancy, carried out an independent review of
the disclosures and concluded that the methodology and assumptions used comply
with the European Embedded Value Principles and European guidance on embedded
value.
* This news item contains information that is subject to the transparency
regulations for listed companies.
Press Embedded Value 2011 ENG:
http://hugin.info/133947/R/1502039/437401.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: KBC Groep via Thomson Reuters ONE
[HUG#1502039]
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.